The detection of molecular measurable residual disease (MRD) for acute myeloid leukemia (AML) has shown promise as a prognostic tool for AML. To support clinical and translational research into potential strategies for MRD monitoring applications in the future, we set out to develop a highly sensitive and accurate MRD assay.

RESULTS

Table 1. Oncomine™ Myeloid MRD Assay DNA panel content

Table 2. Oncomine™ Myeloid MRD Assay RNA panel content

RESULTS

ABSTRACT

The detection of molecular measurable residual disease (MRD) for acute myeloid leukemia (AML) has shown promise as a prognostic tool for AML. To support clinical and translational research into potential strategies for MRD monitoring applications in the future, we set out to develop a highly sensitive and accurate MRD assay.

RESULTS

Table 1. Oncomine™ Myeloid MRD Assay DNA panel content

Table 2. Oncomine™ Myeloid MRD Assay RNA panel content

RESULTS

ABSTRACT

The detection of molecular measurable residual disease (MRD) for acute myeloid leukemia (AML) has shown promise as a prognostic tool for AML. To support clinical and translational research into potential strategies for MRD monitoring applications in the future, we set out to develop a highly sensitive and accurate MRD assay.

RESULTS

Table 1. Oncomine™ Myeloid MRD Assay DNA panel content

Table 2. Oncomine™ Myeloid MRD Assay RNA panel content

REFERENCES


REFERENCES